Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

#1582

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Aim(s): The utility of chromogranin B (CgB), belonging to the same granin family as CgA, was examined as a biomarker for pNET.

Materials and methods: Serum CgB were determined by radioimmunoassay and serum CgA levels by ELISA in patients with pNET (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,